Good morning, and welcome to the Wave Life Sciences Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded and webcast.
Wave Life Sciences has won Food and Drug Administration rare-pediatric-disease designation for its WVE-N531 drug candidate in the neuromuscular genetic disease Duchenne muscular dystrophy. The ...
Fintel reports that on August 9, 2024, Jones Trading initiated coverage of Wave Life Sciences (NasdaqGM:WVE) with a Buy recommendation. As of August 6, 2024, the average one-year price target for ...
Designation highlights significant unmet needs in DMD; dystrophin data from potentially registrational FORWARD-53 trial of WVE-N531 are on track for 3Q 2024 In previous Part A trial, WVE-N531 ...
Wave Life Sciences (WVE) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.20 per share a year ago. These ...
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results